CRO Phastar pens tech deal with newly bought out Medidata

InterSystems Clinical Trial
CRO Phastar pens technology deal with Medidata Solutions as the clinical trial firm is being bought out by French company Dassault Systemes. (InterSystems)

Phastar has signed up to use Medidata Solutions' trial cloud technology with an eye on boosting its work in the U.S.

Under the deal, financial details of which were not made public, trial and data science specialist Phastar will use Medidata’s so-called Rave Clinical Cloud, which the company says in a statement will allow "Phastar to design and conduct complex clinical trials and turn large volumes of data into insights.”

The CRO recently expanded its data operations teams in Kenya and the U.K. and also cut the ribbon on its second U.S. office in Boston; its partnership with Medidata will “further power its U.S. expansion,” it added. 

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

This also comes a week after Medidata Solutions was bought out by France’s Dassault Systemes in a $5.7 billion deal.

RELATED: Dassault Systemes eyes life science boost with $5.7B Medidata buy

Andrew MacGarvey, managing director at Phastar, said: “I am pleased to expand our offering following the addition of the Medidata platform to our technology solutions. Our Data Operations team delivers excellent services across the world and Medidata will allow the team to service projects more efficiently as they work within the unified platform.

“Our new Data Sciences group is developing tools and techniques to help our customers maximize the data they collect. Medidata understands that the types of data collected during clinical trials are changing and the amount of data underpinning clinical research is increasing extremely quickly. We hope to work closely with their team as our customer needs evolve over the coming years.”

Suggested Articles

Gilead Chief Scientific Officer and R&D chief John McHutchison, M.D., is leaving one year after he replaced R&D lead Norbert Bischofberger, Ph.D.

Elon Musk pulled back the curtain on his brain interface-developing Neuralink, saying the startup holds the promise of merging people with AI.

Astellas will develop Frequency's hearing loss drug outside the U.S. in exchange for $80 million upfront and the promise of $545 million down the line.